Clinical trials: Eye Cancer, Intraocular Melanoma
Intraocular Melanoma, Melanoma (Skin)
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of melanoma by stopping blood flow to the tumor.
- Trial name
- NCT00005815
- Testing
- temozolomide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
This phase II trial is studying how well VEGF Trap works in treating patients with recurrent stage III or stage IV melanoma that cannot be removed by surgery.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma
- Trial name
- NCT00450255
- Testing
- ziv-aflibercept, pharmacological study
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Uveal Neoplasms
The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases
A randomized controlled, open-label, multi-centre study evaluating if Isolated Hepatic Perfusion (IHP) increases Overall Survival compared with Best Alternative Care (BAC) in patients with isolated liver metastases from uveal…
- Trial name
- SCANDIUM (NCT01785316)
- Testing
- IHP
- Where
- Sweden
- Volunteers
- 93 people
- Sponsor
- Vastra Gotaland Region
Uveal Melanoma
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Primary objective is to define the maximum tolerated dose (MTD) for the combination of AEB071 and BYL719. Secondary objectives are to define the safety and tolerability of AEB071 and BYL719.
- Trial name
- NCT02273219
- Testing
- AEB071, BYL719
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Columbia University
Uveal Melanoma
Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma
The objectives of the study are the morpho-phenotypic evaluation of uveal melanoma and to identify molecular prognostic factors that may be correlated with disease severity, tumour progression and response to treatment.
- Trial name
- MicroGenUM (NCT05889481)
- Testing
- cytogenetic analysis on tumour tissue, Digital Pathology
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cancer
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may increase the number of immune cells found in…
- Trial name
- NCT00003597
- Testing
- recombinant human thrombopoietin, carboplatin, etoposide
- Where
- 24 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
Intraocular Melanoma, Melanoma (Skin)
Dendritic Cell Vaccination During Lymphoid Reconstruction
This is a randomized, controlled, multicenter, dose-escalation study of fludarabine. Patients are randomized to 1 of 2 treatment arms.
- Trial name
- NCT00313508
- Testing
- Autologous Dendritic Cells (DC), Fludarabine, Autologous Lymphocyte Infusion (ALI)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Uveal Melanoma
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with…
- Trial name
- NCT05415072
- Testing
- DYP688
- Where
- 11 sites in United States, Australia and 5 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Uveal Melanoma
Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma
Plaque radiotherapy is a common treatment for uveal melanoma. However, local failure has been reported in up to 20% of patients.
- Trial name
- NCT00459849
- Testing
- Intraoperative ultrasonography
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- Barnes Retina Institute
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
This randomized phase II trial studies how well trametinib with or without Akt inhibitor GSK2141795 (GSK2141795) works in treating patients with uveal melanoma that has spread to other parts of the body (metastatic).
- Trial name
- NCT01979523
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Trametinib
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma, Liver Metastases
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Patients with uveal melanoma metastatic to the liver will be treated with embolization of the hepatic artery every 4 weeks. GM-CSF (granulocyte-macrophage colony simulating factor) or normal saline will be injected into one of…
- Trial name
- NCT00661622
- Testing
- GM-CSF, Embolization
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
The purpose of this study is to determine whether GSK1120212, a MEK inhibitor, is an effective and safe treatment for cancer subjects with metastatic uveal melanoma and mutation-positive GNAQ or GNA11 metastatic melanoma.
- Conditions
- GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma, Cancer, Metastatic Uveal Melanoma
- Trial name
- NCT01328106
- Testing
- GSK1120212
- Sponsor
- GlaxoSmithKline
Uveal Melanoma
Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
- Trial name
- imMUno (NCT03964298)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Curie
Uveal Melanoma
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
This study has two parts, dose escalation and dose expansion. For dose escalation, the primary objective is to estimate the maximum tolerated dose (MTD) of AEB071 in patients with uveal melanoma.
- Trial name
- NCT01430416
- Testing
- AEB071
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Extraocular Extension Melanoma, Metastatic Intraocular Melanoma
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Extraocular Extension Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma
- Trial name
- NCT01533948
- Testing
- axitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roswell Park Cancer Institute
Ocular Melanoma
Eye Plaque Brachytherapy for Ocular Melanoma
This prospective registry study will evaluate doses utilized in eye plaque brachytherapy for the treatment of ocular melanoma and their associated outcomes.
- Trial name
- PROMPT (NCT06432660)
- Testing
- Data collection
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Duke University
Uveal Melanoma, Liver Metastases
PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases
Uveal melanoma is the most common primary intraocular malignancy in adults. Despite successful control of the primary tumor, metastatic disease will develop in approximately 35%-50% of the patients within 10 years.
- Trial name
- SCANDIUM-III (NCT06519266)
- Testing
- PHP, IPI1/NIVO3, IPI3/NIVO1
- Where
- 6 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Vastra Gotaland Region
Uveal Melanoma, Ocular Melanoma
Study in Subjects With Small Primary Choroidal Melanoma
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with…
- Conditions
- Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
- Trial name
- NCT03052127
- Testing
- Light-activated AU-011, Laser Activation
- Where
- 13 sites in United States
- Volunteers
- 57 people
- Sponsor
- Aura Biosciences
Uveal Melanoma
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
Prospective, open labelled, monocentric trial to evaluation of the circulating tumor DNA rate in the blood, before and after curative resection of hepatic metastasis of uveal melanoma (HMUM) and during post-surgery follow-up
- Trial name
- ctDNA R0 (NCT02849145)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Curie
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.